BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38528726)

  • 21. Clinicopathologic and Prognostic Features of Pediatric Follicular Cell-derived Thyroid Carcinomas: A Retrospective Study of 222 Patients.
    Saliba M; Alzumaili BA; Katabi N; Dogan S; Tuttle RM; Zoltan A; Pandit-Taskar N; Xu B; Ghossein RA
    Am J Surg Pathol; 2022 Dec; 46(12):1659-1669. PubMed ID: 36040037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
    Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
    Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical management.
    Poma AM; Viola D; Macerola E; Proietti A; Molinaro E; De Vietro D; Elisei R; Materazzi G; Miccoli P; Basolo F; Ugolini C
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e4109-e4117. PubMed ID: 34061965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher incidence of tall cell variant of papillary thyroid carcinoma in Graves' Disease.
    Boutzios G; Vasileiadis I; Zapanti E; Charitoudis G; Karakostas E; Ieromonachou P; Karatzas T
    Thyroid; 2014 Feb; 24(2):347-54. PubMed ID: 23786233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular invasion is an independent prognostic factor for distant recurrence-free survival in papillary thyroid carcinoma: a matched-case comparative study.
    Cao J; Hu JL; Chen C; Wang QL; Fang XH; Zhang Y; Ge MH
    J Clin Pathol; 2016 Oct; 69(10):872-7. PubMed ID: 27010434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension.
    Rivera M; Ricarte-Filho J; Tuttle RM; Ganly I; Shaha A; Knauf J; Fagin J; Ghossein R
    Thyroid; 2010 Oct; 20(10):1085-93. PubMed ID: 20860430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Papillary and Medullary Thyroid Carcinomas Presenting as Collision Tumors: A Case Series of 21 Cases at a Tertiary Care Cancer Center.
    Thomas A; Mittal N; Rane SU; Bal M; Patil A; Ankathi SK; Vaish R
    Head Neck Pathol; 2021 Dec; 15(4):1137-1146. PubMed ID: 33840044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer.
    Niederer-Wüst SM; Jochum W; Förbs D; Brändle M; Bilz S; Clerici T; Oettli R; Müller J; Haile SR; Ess S; Stoeckli SJ; Broglie MA
    Surgery; 2015 Jan; 157(1):119-25. PubMed ID: 25482468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications of Extrathyroidal Extension Invading Only the Strap Muscles in Papillary Thyroid Carcinomas.
    Li G; Li R; Song L; Chen W; Jiang K; Tang H; Wei T; Li Z; Gong R; Lei J; Zhu J
    Thyroid; 2020 Jan; 30(1):57-64. PubMed ID: 31830859
    [No Abstract]   [Full Text] [Related]  

  • 31. Liquid-based cytology improves preoperative diagnostic accuracy of the tall cell variant of papillary thyroid carcinoma.
    Lee SH; Jung CK; Bae JS; Jung SL; Choi YJ; Kang CS
    Diagn Cytopathol; 2014 Jan; 42(1):11-7. PubMed ID: 23754825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular and clinical features of papillary thyroid cancer in adult patients with a non-classical phenotype.
    Zhou J; Wang WR; Zhang HF; Gao QQ; Wang WB; Zhu JH; Han YS; Chen J; Ma TH; Zhang XY; Teng XD
    Front Endocrinol (Lausanne); 2023; 14():1138100. PubMed ID: 37124750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Papillary thyroid carcinoma tall cell variant shares accumulation of mitochondria, mitochondrial DNA mutations, and loss of oxidative phosphorylation complex I integrity with oncocytic tumors.
    Tsybrovskyy O; De Luise M; de Biase D; Caporali L; Fiorini C; Gasparre G; Carelli V; Hackl D; Imamovic L; Haim S; Sobrinho-Simões M; Tallini G
    J Pathol Clin Res; 2022 Mar; 8(2):155-168. PubMed ID: 34792302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathological features and molecular characteristics of tall cell and hobnail variants of papillary thyroid carcinoma].
    Zhang M; Duan HL; Wang LM; Gao W; Yao YY; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2021 Nov; 50(11):1234-1239. PubMed ID: 34719160
    [No Abstract]   [Full Text] [Related]  

  • 36. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
    Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Parameters in Differentiated Thyroid Carcinomas.
    Cipriani NA
    Surg Pathol Clin; 2019 Dec; 12(4):883-900. PubMed ID: 31672296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
    Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
    Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
    Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
    J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.